Summary We evaluated the clinical performance of assays measuring intact human chorionic gonadotropin alone (i-hCG), intact and nicked human chorionic gonadotropin (i-hCG and hCGn), free fl-subunit (free f,-hCG) and total fl-human chorionic gonadotropin (t-hCG) using different commercial kits, in a group of bladder carcinoma patients with ectopic human chorionic gonadotropin (hCG) secretion, at diagnosis and during treatment. The diagnostic sensitivity obtained ranged between 63.6% and 75.7% (t-hCG assays), 72.7% (free ,B-hCG assay), 18.2% (i-hCG and hCGn) and 6% (i-hCG assay). Median increases of hCG during treatment in patients with chemotherapy resistance ranged from 4.9 to 6.9 for t-hCG and free fl-hCG assays and from 1.4 to 3.2 for i-hCG and i-hCG plus hCGn assays. Median decreases when chemotherapy was efficient ranged from 2.8 to 3.3 (t-hCG and free ,B-hCG assays) and from 1.1 to 1.5 (i-hCG and i-hCG plus hCGn assays). We conclude that t-hCG and free fl-hCG are the most suitable assays for the management of bladder carcinoma patients as the ectopic secretion of chorionic gonadotropin is mainly due to the free fisubunit.
The determination of human chorionic gonadotropin (hCG) is especially useful in the early detection of pregnancy, ectopic pregnancy or threatened abortion, as well as monitoring gestational trophoblastic disease. Some germ cell tumours are also able to synthesise hCG. Moreover, ectopic production of hCG has been reported in non-trophoblastic tumours in lung, liver, oesophagus, stomach, colon, kidney, gall bladder and urinary bladder (Alfthan et al., 1992; Hattori et al., 1980; Hoermann et al., 1992; Iles and Chard 1991) .
The immunoreactive hCG substance in serum is a mixture of hCG a-and fl-subunit-related molecules including intact hCG, nicked hCG (with missing peptide linkages), hCG missing the fl-subunit c-terminal segment, hCG free f,-subunit, hCG free oc-subunit, hCG fl-subunit core fragment and different carbohydrate variants for hCG (Cole et al., 1992 (Cole et al., , 1993 .
In most clinical situations intact hCG molecule (i-hCG) is the predominant molecular species in peripheral blood, and total fl-hCG assays (intact molecule plus nicked molecule plus free P-subunit) show a reasonably good correlation with assays which measure intact hCG alone or intact plus nicked molecule. However, some choriocarcinomas and testicular cancers may secrete only free fl-subunits, and assays that measure free P-hCG or t-hCG (i-hCG plus hCGn plus free fihCG) are required Madersbacher et al., 1992; Rinker et al., 1989; Saller et al., 1990) . Expression of hCG by bladder cancer is now recognised as being a common phenomenon, the biological function of which is unknown; clinically, it has been associated with advanced disease and radioresistance. Assays measuring free fl-hCG have proved useful in identifying aggressive forms of bladder cancer (Iles et al., 1989; Iles and Chard, 1991; Marcillac et al., 1992; Oliver et al., 1988 Concentrations of hCG were measured in all these patients and the diagnostic sensitivity (certainty of the test in detecting sick persons correctly) using the different hCG assays was calculated. The clinical comparison of these assays was further performed during chemotherapy treatment in 15 patients who presented recurrence of the disease (eight patients with chemotherapic resistance and seven patients with clinical response to chemotherapy). During the treatment period the median number of determinations in each patient was three with a range between 2 and 6.
The procedures were performed in accordance with the guidelines of the ethical committee of our hospital.
Results

Comparison assays
The results obtained in intra-and interserial precision studies (n=20) using the control sera were within the range claimed by the manufacturers. Intraserial imprecision obtained ranged from 2.1% to 9.2% for i-hCG assay, from 3.5% to 10.2% for i-hCG plus hCGn assay, from 3.8% to 6.5% for free 3-hCG assay and from 2.3% to 9.9% for t-hCG assays. Using the same control sera the interserial imprecision ranged from 4.9% to 11% for i-hCG assay, from 5.9% -12.8% for i-hCG plus hCGn assays, from 8.8% -12.1% for free fl-hCG assay and from 3.9% to 12.1% for t-hCG assays. To assess correlation between the four methods measuring t-hCG in the patient samples evaluated (n = 75), we used the nonparametric regression method of Passing-Bablok (Passing et al., 1983 Figure 1 shows the distribution of the concentrations of thCG, i-hCG plus hCGn, i-hCG and free P-hCG measured in the serum of bladder cancer patients studied. Median concentration, range and diagnostic sensitivity of i-hCG, ihCG plus hCGn, free fi-hCG and t-hCG determinations in these patients were calculated ( Table I ). The diagnostic sensitivities using t-hCG assays ranged between 63.6% and 75.7%, and was 72.7% using free fl-hCG assay; with i-hCG plus hCGn assay the diagnostic sensitivity obtained was 18.2% and measuring the i-hCG alone the sensitivity was 6%. Table I shows the ratio (%) between free fl-hCG and thCG, according to the different kits (Fan et al., 1987) . These ratios ranged between 2.2% and 6.6% (kit 2 and kit 4 respectively).
To evaluate the clinical value of the different hCG assays studied during treatment, we calculated ( Figure 2 ) the increases (final/initial concentration) of free fl-hCG, t-hCG, i-hCG plus hCGn and i-hCG concentration in the group of patients that showed resistance to chemotherapy treatment (n=8), and also the decrease (initial/final concentration) in free fl-hCG, t-hCG, i-hCG plus hCGn and i-hCG concentration in the group (n = 7) with clinical response to chemotherapy (Figure 3 ). Median increases obtained using free fi-hCG assay and t-hCG assays ranged from 4.9 to 6.9 and from 1.4 to 3.2 when i-hCG and i-hCG plus hCGn assays were used. Median decreases when chemotherapy was efficient ranged from 2.8 to 3.3 (t-hCG and free ,B-hCG assays) and from 1.1 to 1.5 (i-hCG and i-hCG plus hCGn assays). Figure 4 is an example of the performance of i-hCG, i-hCG plus hCGn, t-hCG and free ,B concentrations during the treatment period in a patient who is at present in complete remission.
Discussion
The regression study among t-hCG kits showed a proportional error when kit 1 was compared with kit 2, kit 3 and kit 4 (confidence intervals of the slope did not include 1.0) and a constant error when kit 1 was compared with kit 2 (confidence intervals of the y-intercept did not include 0). Variation in t-hCG results was not attributed to differences in hCG standards because the four kits were standardised against the WHO first IRP 75/537 reference material.
Moreover, the four kits used a combination of anti-# (immobilised) -anti-fl (labelled) sandwich assay. Kit 3 was the only kit in which both antibodies were monoclonal. Kits 1 and 4 used a polyclonal antibody as a labelled antibody and in kit 2 the polyclonal antibody was the immobilised one.
The difference in recognition of the free # fraction by the different antibodies used in the four t-hCG immunoassays assayed was possibly the cause of the higher or lower results obtained.
The diagnostic sensitivities using t-hCG assays were similar to those obtained with free fl-hCG assay. As we commented earlier, because the aim of our study was to compare the efficiency of different hCG assay, we specifically selected patients with raised hCG values and, therefore, the diagnostic sensitivities obtained were higher than those of other authors (Dexeus et al., 1986; Iles et al., 1989; McLoughlin et al., 1991; Smith et al., 1994) . Kit 1 and kit hCG fraction. This is important when evaluating different thCG assays because the free f-subunit and the free fl/t-hCG ratio varied depending on the stage of tumour progression and higher values are associated with malignant and invasive forms of choriocarcinomas (Fan et al., 1987) . As shown in Figure 1 and in Table I , the assay measuring both fractions, intact plus nicked hCG, performed better than the assay measuring intact fraction alone. Recognition of nicked hCG, however, does not seem to be crucial in the use of hCG as a tumour marker in bladder carcinomas, as it was not in testicular cancer (Hoerman et al., 1994) . When chemotherapy was efficient the four kits of t-hCG studied proved to be as useful as free fl-hCG assay; however, in more aggressive forms of bladder carcinoma the assays with the best performance were the free fl-hCG and the t-hCG assays with high free fraction affinity. There is accumulating evidence indicating that the isolated production of free fl-hCG may be associated with aggressive trophoblastic and non-trophoblastic malignancies (Cole et al., 1993; Marcillac et al., 1992; Rinker et al., 1989; Saller et al., 1990) . Like others, (Iles et al., 1989; McLoughlin et al., 1991; Smith et al., 1994) , we found no correlation between the hCG concentration and the tumour grade. Moreover, there seems to be no correlation between the hCG concentration and tumour DNA-ploidy and S-phase fraction according to other studies (Fossa et al., 1993) .
In conclusion, for the routine use of serum chorionic gonadotropin as a tumour marker in patients with bladder carcinoma, care must be taken in choosing hCG kits as the ihCG and i-hCG plus hCGn concentration does not reflect the disease and does not detect exclusive secretion of free fi fraction. On the other hand, t-hCG assays with high affinity for free fi fraction and the free fl-hCG assay seem to be the most reliable and best choice in the management of aggressive forms of bladder carcinoma.
Abbreviations hCG, human chorionic gonadotrophin; i-hCG, intact or nonnicked molecule of human chorionic gonadotropin; hCGn, nicked molecule of human chorionic gonadotrophin; free ,B-hCG, free beta subunit of human chorionic gonadotrophin; t-hCG, total beta human chorionic gonadotropin (intact molecule plus nicked molecule plus free ,B-subunit).
